Literature DB >> 16024834

Intravitreal triamcinolone therapy for diabetic macular oedema.

S A Vernon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16024834      PMCID： PMC1772788          DOI： 10.1136/bjo.2005.065805

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  21 in total

1.  Intraocular pressure after intravitreal injection of triamcinolone acetonide.

Authors:  J B Jonas; I Kreissig; R Degenring
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

2.  Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study.

Authors:  A P Ciardella; J Klancnik; W Schiff; G Barile; K Langton; S Chang
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

3.  Intravitreal triamcinolone for refractory diabetic macular edema.

Authors:  Adam Martidis; Jay S Duker; Paul B Greenberg; Adam H Rogers; Carmen A Puliafito; Elias Reichel; Caroline Baumal
Journal:  Ophthalmology       Date:  2002-05       Impact factor: 12.079

4.  Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane.

Authors:  T Yamamoto; N Akabane; S Takeuchi
Journal:  Am J Ophthalmol       Date:  2001-09       Impact factor: 5.258

5.  Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial.

Authors:  Florian K P Sutter; Judy M Simpson; Mark C Gillies
Journal:  Ophthalmology       Date:  2004-11       Impact factor: 12.079

6.  Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial.

Authors:  Mark C Gillies; Judy M Simpson; Frank A Billson; Wei Luo; Philip Penfold; William Chua; Paul Mitchell; Meidong Zhu; Alex B L Hunyor
Journal:  Arch Ophthalmol       Date:  2004-03

7.  Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema.

Authors:  François Audren; Michel Tod; Pascale Massin; Rym Benosman; Belkacem Haouchine; Ali Erginay; Charles Caulin; Alain Gaudric; Jean-François Bergmann
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-10       Impact factor: 4.799

8.  Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema.

Authors:  Jost B Jonas; Robert F Degenring; Bernd A Kamppeter; Ingrid Kreissig; Imren Akkoyun
Journal:  Am J Ophthalmol       Date:  2004-07       Impact factor: 5.258

9.  Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial.

Authors:  Pascale Massin; François Audren; Belkacem Haouchine; Ali Erginay; Jean-François Bergmann; Rym Benosman; Charles Caulin; Alain Gaudric
Journal:  Ophthalmology       Date:  2004-02       Impact factor: 12.079

10.  Intravitreal injection of triamcinolone for diffuse diabetic macular edema.

Authors:  Jost B Jonas; Ingrid Kreissig; Antje Söfker; Robert F Degenring
Journal:  Arch Ophthalmol       Date:  2003-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.